Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Zelicapavir for Respiratory Syncytial Virus Infection in Adults Who Are at High Risk for Severe Disease
NCT07908381 is registered in ClinicalTrials.gov with Enanta Pharmaceuticals, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Zelicapavir for Respiratory Syncytial Virus Infection in Adults Who Are at High Risk for Severe Disease
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Phase
- Phase 2/3
- Overall status
- Recruiting
- Start date
- October 19, 2026
- Completion date
- July 31, 2029
- Enrollment
- 860 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
rsv
Arms
As registered; 2 arms.
-
zelicapavir
Zelicapavir 800 mg, orally
-
Placebo
Matching placebo, orally
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Time to complete resolution of all 13 RSV symptoms as assessed by the Respiratory Infection Intensity and Impact Questionnaire (RiiQ) symptom scale
Lead sponsor's other trials
Enanta Pharmaceuticals, Inc, most recent start first.
+40 more trials See the organization page
Similar trials
Same condition (Pulmonary Disease, Chronic Obstructive) and phase, most recent start first.
+34 more trials See the condition page